{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:28:46Z","timestamp":1793921326227,"version":"4.8.0"},"reference-count":29,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"ImmuneSensor Therapeutics","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"https:\/\/ror.org\/00zm09144","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,5,29]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite progress in cancer therapeutics, there remains an unmet need for treatment of advanced solid tumors. The cGAS-cGAMP-STING pathway plays a pivotal role in innate antitumor immunity processes. IMSA101 is a small molecule analog of cGAMP and a potent STING agonist. Preclinical studies demonstrate antitumor activity of IMSA101 alone and in combination with immune-checkpoint inhibitors (ICIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>IMSA101-101 was an open-label, multicenter, phase 1 first-in-human dose-escalation study to establish a recommended phase 2 dose (RP2D) of IMSA101 both as monotherapy and in combination with a programmed death ligand 1 (PD-(L)1)-ICI. Secondary objectives were to evaluate safety, tolerability and antitumor activity, and to characterize pharmacokinetics. Adult patients with advanced solid tumors with \u22652 Response Evaluation Criteria in Solid Tumors evaluable lesions, at least one of these suitable for injection, were enrolled. IMSA101 was administered by intratumoral injection with weekly injections for the first 3 weeks, followed by biweekly injections. The dose escalation explored doses of 100\u20131,200\u2009\u00b5g (monotherapy) and 800\u20132,400\u2009\u00b5g (combination therapy with ICI) in a 3+3 design. No formal statistical analysis was planned for this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>40 patients (22 monotherapy, 18 combination therapy) received at least one dose of IMSA101. IMSA101 1,200\u2009\u00b5g (monotherapy) and 2,400\u2009\u00b5g (combination therapy) doses, well-tolerated and associated with signs of antitumor activity, were selected as provisional RP2Ds. The most common IMSA101-related treatment-emergent adverse events (TEAEs) were injection site pain (8 (36.4%)) and fatigue (4 (18.2%)) for monotherapy and chills (3 (16.7%)), injection site pain (2 (11.1%)), and fever (2 (11.1%)) for combination therapy. No clear dose-response relationship between IMSA101 and occurrence of TEAEs was observed. The elimination half-life of plasma IMSA101 was approximately 1.5\u20132\u2009hours, with no reported plasma accumulation. With monotherapy, no patients achieved complete response (CR) or partial response (PR), so overall response rate (ORR) was not determined; 17 (77.3%) patients had progressive disease (PD) and one patient (4.5%, 400\u2009\u00b5g cohort) had stable disease (SD) as best response. With combination therapy, ORR was 5.6%; remaining patients had PD (10 (55.6%)) and SD (2 (11.1%)) as their best response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IMSA101 doses of 1,200\u2009\u00b5g (monotherapy arm) and 2,400\u2009\u00b5g (combination therapy arm) were well tolerated but demonstrated minimal signals of antitumor activity in patients with advanced solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04020185\">NCT04020185<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-011572","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T09:30:11Z","timestamp":1750239011000},"page":"e011572","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":33,"title":["Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04020185","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04420884","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05514717","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05471856","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06021626","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06626633","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9184-6019","authenticated-orcid":false,"given":"Jay","family":"Jacoby","sequence":"first","affiliation":[{"name":"HonorHealth Research Institute, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deva","family":"Mahalingam","sequence":"additional","affiliation":[{"name":"Northwestern Memorial Hospital, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Alistar","sequence":"additional","affiliation":[{"name":"Morristown Medical Center, Atlantic Health System Inc, Morristown, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Garmey","sequence":"additional","affiliation":[{"name":"Immunesensor Therapeutics Inc, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Kazmi","sequence":"additional","affiliation":[{"name":"UT Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Mooneyham","sequence":"additional","affiliation":[{"name":"Immunesensor Therapeutics Inc, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Sun","sequence":"additional","affiliation":[{"name":"Immunesensor Therapeutics Inc, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A","family":"Yap","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vu","sequence":"additional","affiliation":[{"name":"UC San Diego Health Moores Cancer Center, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0643-6759","authenticated-orcid":false,"given":"Justin","family":"Moser","sequence":"additional","affiliation":[{"name":"HonorHealth Research Institute, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"2025100309563496000_13.6.e011572.1","doi-asserted-by":"crossref","DOI":"10.1186\/s40169-018-0185-6","article-title":"Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs","volume":"7","author":"Maeda","year":"2018","journal-title":"Clin Transl Med"},{"key":"2025100309563496000_13.6.e011572.2","doi-asserted-by":"crossref","DOI":"10.1038\/s41378-023-00616-x","article-title":"Microphysiological systems for solid tumor immunotherapy: opportunities and challenges","volume":"9","author":"Abizanda-Campo","year":"2023","journal-title":"Microsyst Nanoeng"},{"key":"2025100309563496000_13.6.e011572.3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1621363114"},{"key":"2025100309563496000_13.6.e011572.4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.24272\/j.issn.2095-8137.2022.464","article-title":"Current understanding of the cGAS-STING signaling pathway: Structure, regulatory mechanisms, and related diseases","volume":"44","author":"Pan","year":"2023","journal-title":"Zool Res"},{"key":"2025100309563496000_13.6.e011572.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139"},{"key":"2025100309563496000_13.6.e011572.6","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-47692-9","article-title":"The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion","volume":"15","author":"Uslu","year":"2024","journal-title":"Nat Commun"},{"key":"2025100309563496000_13.6.e011572.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025100309563496000_13.6.e011572.8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2013.00193","article-title":"Strategies to increase drug penetration in solid tumors","volume":"3","author":"Choi","year":"2013","journal-title":"Front Oncol"},{"key":"2025100309563496000_13.6.e011572.9","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"2025100309563496000_13.6.e011572.10","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0761"},{"key":"2025100309563496000_13.6.e011572.11","doi-asserted-by":"crossref","DOI":"10.1016\/j.mtbio.2023.100839","article-title":"Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: A comprehensive review of strategies and future perspectives","volume":"23","author":"Huang","year":"2023","journal-title":"Mater Today Bio"},{"key":"2025100309563496000_13.6.e011572.12","doi-asserted-by":"crossref","DOI":"10.3892\/or.2023.8682","article-title":"STING promotes invasion and migration of uveal melanoma through p38\u2011MAPK signaling","volume":"51","author":"Zhou","year":"2024","journal-title":"Oncol Rep"},{"key":"2025100309563496000_13.6.e011572.13","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00916-z","article-title":"cGAS-STING, an important pathway in cancer immunotherapy","volume":"13","author":"Jiang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2025100309563496000_13.6.e011572.14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1705499114"},{"key":"2025100309563496000_13.6.e011572.15","doi-asserted-by":"publisher","DOI":"10.1038\/srep39858"},{"key":"2025100309563496000_13.6.e011572.16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.omtn.2018.11.003","article-title":"An Analysis of the Expression and Association with Immune Cell Infiltration of the cGAS\/STING Pathway in Pan-Cancer","volume":"14","author":"An","year":"2019","journal-title":"Molecular Therapy - Nucleic Acids"},{"key":"2025100309563496000_13.6.e011572.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.016"},{"key":"2025100309563496000_13.6.e011572.18","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ccell.2022.05.016","article-title":"The local microenvironment matters in preclinical basic and translational studies of cancer immunology and immunotherapy","volume":"40","author":"Ho","year":"2022","journal-title":"Cancer Cell"},{"key":"2025100309563496000_13.6.e011572.19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3642"},{"key":"2025100309563496000_13.6.e011572.20","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0438"},{"key":"2025100309563496000_13.6.e011572.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1963"},{"key":"2025100309563496000_13.6.e011572.22","article-title":"1030P Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors","volume":"34","author":"Calvo","year":"2023","journal-title":"Ann Oncol"},{"key":"2025100309563496000_13.6.e011572.23","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy424.015","article-title":"Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas","volume":"29","author":"Harrington","year":"2018","journal-title":"Ann Oncol"},{"key":"2025100309563496000_13.6.e011572.24","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9103323","article-title":"Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy","volume":"9","author":"Motedayen Aval","year":"2020","journal-title":"J Clin Med"},{"key":"2025100309563496000_13.6.e011572.25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1456"},{"key":"2025100309563496000_13.6.e011572.26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301419"},{"key":"2025100309563496000_13.6.e011572.27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601999"},{"key":"2025100309563496000_13.6.e011572.28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6166"},{"key":"2025100309563496000_13.6.e011572.29","doi-asserted-by":"crossref","unstructured":"Khorsandi S , Huntoon K , Wang Y , et al . Targeted STING Activation Using Modified Ultrasound-Responsive Microbubbles Enhances Immune Checkpoint Blockade Against Melanoma. Adv Sci (Weinh) 2025.:e2416596. doi:10.1002\/advs.202416596","DOI":"10.1002\/advs.202416596"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-011572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:56:47Z","timestamp":1759510607000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-011572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,18]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/jitc-2025-011572"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-011572","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}